In these triple-negative breast tumors the effect is likely to be entirely attributable to EGFR inhibition, and was reflected by significant inhibition of pEGFR by gefitinib treatment in HCC1806 tumor tissue, although the inhibition by gefitinib alone was not significant in MDA-MB-468 tumors. Here, EGFR is linked to neoplasm.